Fluoxetine Prevention Trial

Withdrawn before enrolling · Early Phase 1 · Has a placebo group

Conditions studied: Cognitive Dysfunction

In brief

Many cancer survivors are experiencing problems with memory and other cognitive abilities following cancer treatment. Little is known concerning the contributions of potentially preventive therapies on cognitive function, but animal studies have pointed to the potential value of the medication fluoxetine in this context. We aim to determine whether six months of fluoxetine therapy can preserve brain function in patients who have undergone chemotherapy, and examine potential biological mechanisms for its protective effects in humans. If use of fluoxetine in cancer patients can be validated in this manner, it will represent the first drug demonstrated to prevent cerebral dysfunction associated with exposure to chemotherapy. Moreover, as this involves an agent that is already FDA-cleared for other indications, widely commercially available throughout the U.S. and other parts of the world, and relatively inexpensive since it is obtainable in generic formulations, it would represent a pharmacologic approach that is amenable to rapid translation to the clinical setting.

Key facts

Study ID

NCT01615055

Run by

University of California, Los Angeles

People needed

0

Starts

2018-06-01

Expected to finish

2020-10-01

Last updated by the study team

2018-10-15

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Scheduled to undergo chemotherapy, or has completed chemotherapy no more than a month prior to enrollment, for breast cancer or lymphoma
• Age 21 or above
• Geographically accessible for follow-up in one year
• English language proficient
• Able to provide informed consent

You may not qualify if…

• Pregnant
• Evidence of current or past disorder/disease of the central nervous system or any medical condition that might be expected to impact cognitive functioning (e.g. multiple sclerosis)
• History of head trauma with loss of consciousness greater than 30 minutes
• Epilepsy, dementia, or severe learning disability
• Current psychotic-spectrum disorder (e.g. schizophrenia, bipolar disorder, major affective disorder) or current substance abuse or dependence
• History of whole brain irradiation or surgery
• Active diagnosis of autoimmune disorder e.g., systemic lupus erythematosis, rheumatoid arthritis, vasculitis
• Insulin dependent diabetes
• Uncontrolled allergic condition or asthma
• Chronic use of oral steroid medication
• Hormone therapy (estrogen, progestin compounds) other than vaginal estrogen
• Due to the subtleties of neuropsychological test evaluation, including necessity for repeated administration with alternate forms, we must also exclude non-English language proficient subjects.

Where it is running

• City of Hope — Duarte, California, United States
• UCLA Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.